Ignite Creation Date:
2025-12-25 @ 1:18 AM
Ignite Modification Date:
2025-12-25 @ 11:26 PM
Study NCT ID:
NCT03951493
Status:
UNKNOWN
Last Update Posted:
2022-04-28
First Post:
2019-05-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077211', 'term': 'Zoledronic Acid'}, {'id': 'D012996', 'term': 'Solutions'}, {'id': 'D007267', 'term': 'Injections'}], 'ancestors': [{'id': 'D004164', 'term': 'Diphosphonates'}, {'id': 'D063065', 'term': 'Organophosphonates'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D007093', 'term': 'Imidazoles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}, {'id': 'D004333', 'term': 'Drug Administration Routes'}, {'id': 'D004358', 'term': 'Drug Therapy'}, {'id': 'D013812', 'term': 'Therapeutics'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 225}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2020-06-23', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-04', 'completionDateStruct': {'date': '2023-11-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2022-04-21', 'studyFirstSubmitDate': '2019-05-10', 'studyFirstSubmitQcDate': '2019-05-14', 'lastUpdatePostDateStruct': {'date': '2022-04-28', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-05-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-11-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Differential Cost Result Ratio (DCRR) expressed as cost per year of life earned in good health', 'timeFrame': '24 months', 'description': 'The determination of the DCRR includes Identification of care consumption ; The measurement of costs ; overall survival at 2 years ; Calculation of utilities using the EQ5D-5L questionnaire'}], 'secondaryOutcomes': [{'measure': 'Survival without vertebral compression fractures', 'timeFrame': 'At 12 months and 24 months'}, {'measure': 'Pain control', 'timeFrame': 'at inclusion, 12 and 24 months', 'description': "Pain control will be assessed using a visual analogue scale (VAS) that measures pain intensity, prevents it, initiates or monitors drug or non-drug treatment, and the Brief Pain inventory, a questionnaire that quickly assesses the severity of pain and its impact on the patient's daily life."}, {'measure': 'Survival without bone complication', 'timeFrame': 'At 12 months and 24 months'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Hypo-fractured radiotherapy in stereotactic conditions (RSHF)', 'zoledronic acid', 'medico-economic', 'vertebral compressive fracture'], 'conditions': ['Vertebral Metastasis']}, 'descriptionModule': {'briefSummary': 'Hypo-fractured radiotherapy in stereotactic conditions (RSHF) of bone metastases allows high doses to be delivered to the affected bone segment while sparing adjacent healthy tissues as well as possible. In addition, it not only reduces pain and prevents spinal cord compression, but also improves long-term control of metastatic disease.\n\nZoledronic acid reduces bone complications. The economic literature shows that stereotactic radiotherapy, like zoledronic acid, are cost-effective strategies in these indications. The objective of this research project is to evaluate the efficiency of adding zoledronic acid to stereotactic radiotherapy in the treatment of vertebral metastases.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Cancer with inoperable thoracic and/or lumbar vertebral metastasis;\n* Age ≥ 18 years old ;\n* Life expectancy greater than 1 year;\n* OMS or PS ≤ 2 ;\n* Effective contraception for women of childbearing age;\n* Patient information and free, informed and written consent, signed by the patient and investigator;\n* Patient affiliated or beneficiary of the social security system.\n\nExclusion Criteria:\n\n* Cancer with inoperable thoracic and/or lumbar vertebral metastasis;\n* Painful patient unable to maintain a lying position for 30 minutes despite analgesic treatment;\n* Patient who has received external irradiation from the proposed irradiation area \\> 20 Gy ;\n* Signs of neurological compression;\n* Spinal cord compression or epidural damage requiring surgery before radiotherapy;\n* Clinically significant hypersensitivity to zoledronic acid, other bisphosphonates or any excipient;\n* History of osteonecrosis of the maxilla or bone exposure or delayed healing after dental surgery;\n* Previous (less than 2 years) or ongoing treatment with a bisphosphonate;\n* Creatinine clearance \\< 30 ml/min;\n* Pregnant or breastfeeding woman;\n* Patient protected or under guardianship or incapable of giving consent;\n* Impossibility to submit to the medical follow-up of the trial for geographical, social or psychological reasons.'}, 'identificationModule': {'nctId': 'NCT03951493', 'acronym': 'ZOSTER', 'briefTitle': 'Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases', 'organization': {'class': 'OTHER', 'fullName': "Institut Cancerologie de l'Ouest"}, 'officialTitle': 'Phase III Randomized, Controlled, Open, Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases', 'orgStudyIdInfo': {'id': 'ICO-N-2018-14'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'RSHF + zoledronic acid', 'description': 'Patients receive RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction. combined with zoledronic acid (4 mg IV slow monthly for 12 months, dose adjusted according to creatinine clearance).', 'interventionNames': ['Combination Product: Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'RSHF', 'description': 'Patients receive only RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction.', 'interventionNames': ['Radiation: Hypo-fractured radiotherapy in stereotactic conditions']}], 'interventions': [{'name': 'Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions', 'type': 'COMBINATION_PRODUCT', 'description': "All patients receive radiotherapy i.e. treatment on D1, D3 and D5.\n\nSeveral radiotherapy schemes are possible:\n\n* 20 Gy in 1 fraction;\n* 27 Gy in 3 fractions of 9 Gy\n* 30 Gy in 5 fractions of 6 Gy. All patients in the experimental arm receive an intravenous injection of at least 15 minutes of 4 mg zoledronic acid every month for 12 months.\n\nThe first injection must be made no more than 3 weeks before the first day of radiotherapy. It can be performed up to J1 of radiotherapy.\n\nThe injections will be carried out either at the patient's home by the nurses or in the investigator centre.", 'armGroupLabels': ['RSHF + zoledronic acid']}, {'name': 'Hypo-fractured radiotherapy in stereotactic conditions', 'type': 'RADIATION', 'description': 'All patients receive radiotherapy i.e. treatment on D1, D3 and D5.\n\nSeveral radiotherapy schemes are possible:\n\n* 20 Gy in 1 fraction;\n* 27 Gy in 3 fractions of 9 Gy\n* 30 Gy in 5 fractions of 6 Gy.', 'armGroupLabels': ['RSHF']}]}, 'contactsLocationsModule': {'locations': [{'zip': '33000', 'city': 'Bordeaux', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Stéphanie BATARD, MD', 'role': 'CONTACT', 'email': 's.batard@bordeaux.unicancer.fr'}, {'name': 'Stéphanie BATARD, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Institut BERGONIE', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'city': 'Nancy', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'JEAN-CHRISTOPHE FAIVRE, MD', 'role': 'CONTACT', 'email': 'jc.faivre@nancy.unicancer.fr'}, {'name': 'Jean-Christophe FAIVRE, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Institut de Cancérologie de Lorraine', 'geoPoint': {'lat': 48.68439, 'lon': 6.18496}}, {'zip': '44277', 'city': 'Nantes', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'Xavier BUTHAUD, MD', 'role': 'CONTACT', 'email': 'xavier.buthaud@groupeconfluent.fr'}, {'name': 'Xavier BUTHAUD, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hôpital Privé du Confluent', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '06000', 'city': 'Nice', 'status': 'NOT_YET_RECRUITING', 'country': 'France', 'contacts': [{'name': 'René-Jean BENSADOUN, MD', 'role': 'CONTACT', 'email': 'renejean.bensadoun@che-nice.com'}, {'name': 'René-Jean BENSADOUN, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centre de Haute Energie', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'zip': '69310', 'city': 'Pierre-Bénite', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Ariane LAPIERRE, MD', 'role': 'CONTACT', 'email': 'ariane.lapierre@chu-lyon.fr'}, {'name': 'Ariane LAPIERRE, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hopital Lyon Sud', 'geoPoint': {'lat': 45.70359, 'lon': 4.82424}}, {'zip': '76038', 'city': 'Rouen', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'SEBASTIEN THUREAU, MD', 'role': 'CONTACT', 'email': 'sebastien.thureau@chb.unicancer.fr'}, {'name': 'Sébastien THUREAU, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Centre Henri Becquerel', 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'zip': '44805', 'city': 'Saint-Herblain', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Stéphane SUPIOT, MD', 'role': 'CONTACT', 'email': 'stephane.supiot@ico.unicancer.fr', 'phone': '+33240679900'}, {'name': 'Stéphane SUPIOT, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Stéphane SUPIOT', 'geoPoint': {'lat': 47.21154, 'lon': -1.651}}], 'centralContacts': [{'name': 'Stéphane SUPIOT, MD', 'role': 'CONTACT', 'email': 'stephane.supiot@ico.unicancer.fr', 'phone': '+33240679900'}], 'overallOfficials': [{'name': 'Stéphane SUPIOT, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'ICO site SAINT HERBLAIN'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': "Institut Cancerologie de l'Ouest", 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}